Ascensia, Dexcom bundle diabetes products

Wednesday, July 19, 2017

PARSIPPANY, N.J. – Ascensia Diabetes Care and Dexcom have hammered out a commercial agreement that they expect to increase access to the Dexcom G5 continuous glucose monitoring system. Per the agreement, Ascensia’s ContourNext One blood glucose monitoring system will be provided in the bundle of supplies for the Dexcom G5. The role of the ContourNext: to provide highly accurate readings for CGM calibration, something people who use the G5 do on a regular basis to verify sensor readings are on track. This “complete bundle” will be available to people with diabetes who are covered by Medicare and qualify for “therapeutic” CGM, according to a press release. “With this agreement, we are pleased to begin offering a complete bundle to Medicare-eligible patients, enabling access to the Dexcom G5 as efficiently as possible,” said Rick Doubleday, chief commercial officer at Dexcom. Earlier this year, CMS decided to classify certain CGMs as DME, if, among other criteria, they’re “therapeutic” and approved by the U.S. Food and Drug Administration for use in place of blood glucose monitors for making diabetes treatment decisions.